Kyverna Therapeutics (NASDAQ:KYTX) Releases Quarterly Earnings Results, Beats Expectations By $0.05 EPS

Kyverna Therapeutics (NASDAQ:KYTX) posted its quarterly earnings results on Wednesday. The company reported ($0.63) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05, FiscalAI reports.

Kyverna Therapeutics Trading Up 0.4%

NASDAQ:KYTX opened at $8.05 on Thursday. The company has a debt-to-equity ratio of 0.13, a current ratio of 8.15 and a quick ratio of 8.15. The firm has a market capitalization of $489.36 million, a P/E ratio of -2.74 and a beta of 1.93. Kyverna Therapeutics has a 12-month low of $2.95 and a 12-month high of $13.67. The business has a 50 day simple moving average of $8.06 and a 200 day simple moving average of $8.45.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Public Employees Retirement System of Ohio acquired a new position in Kyverna Therapeutics during the 3rd quarter valued at about $28,000. Qube Research & Technologies Ltd bought a new stake in Kyverna Therapeutics in the second quarter worth about $43,000. Rhumbline Advisers lifted its stake in Kyverna Therapeutics by 22.0% during the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after purchasing an additional 5,694 shares during the last quarter. Ameriprise Financial Inc. acquired a new position in shares of Kyverna Therapeutics in the 3rd quarter worth $77,000. Finally, Bank of America Corp DE lifted its stake in Kyverna Therapeutics by 41.6% during the fourth quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock valued at $81,000 after buying an additional 6,400 shares in the last quarter. Institutional investors own 18.08% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently issued reports on KYTX. Wall Street Zen downgraded shares of Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. JPMorgan Chase & Co. reduced their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Kyverna Therapeutics in a report on Wednesday, June 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Kyverna Therapeutics in a report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

Kyverna Therapeutics Company Profile

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.